157 related articles for article (PubMed ID: 22672562)
1. A CD3+ count-based thymoglobulin induction regimen permits delayed introduction of calcineurin inhibitors in kidney transplantation.
Wang CJ; Tuffaha A; Zhang D; Diederich DA; Wetmore JB
Clin Transplant; 2012; 26(6):900-9. PubMed ID: 22672562
[TBL] [Abstract][Full Text] [Related]
2. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes.
Foster CE; Weng RR; Piper M; Laugenou K; Ichii H; Lakey J; Malinoski D
Transplant Proc; 2012 Jan; 44(1):164-6. PubMed ID: 22310605
[TBL] [Abstract][Full Text] [Related]
3. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
[TBL] [Abstract][Full Text] [Related]
4. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients.
Peddi VR; Bryant M; Roy-Chaudhury P; Woodle ES; First MR
Transplantation; 2002 May; 73(9):1514-8. PubMed ID: 12023634
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.
Gonwa TA; Mai ML; Smith LB; Levy MF; Goldstein RM; Klintmalm GB
Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785
[TBL] [Abstract][Full Text] [Related]
6. Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance.
Krepsova E; Tycova I; Sekerkova A; Wohlfahrt P; Hruba P; Striz I; Sawitzki B; Viklicky O
BMC Nephrol; 2015 Aug; 16():146. PubMed ID: 26286066
[TBL] [Abstract][Full Text] [Related]
7. Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience.
Huang HF; Zhou JY; Xie WQ; Wu JY; Deng H; Chen JH
Int Urol Nephrol; 2016 Aug; 48(8):1363-1370. PubMed ID: 27170340
[TBL] [Abstract][Full Text] [Related]
8. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
Gentile G; Somma C; Gennarini A; Mastroluca D; Rota G; Lacanna F; Locatelli B; Remuzzi G; Ruggenenti P
Am J Nephrol; 2015; 41(1):16-27. PubMed ID: 25612603
[TBL] [Abstract][Full Text] [Related]
9. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age.
Patel SJ; Knight RJ; Suki WN; Abdellatif A; Duhart BT; Krauss AG; Mannan S; Nezakatgoo N; Osama Gaber A
Clin Transplant; 2011; 25(3):E250-6. PubMed ID: 21231963
[TBL] [Abstract][Full Text] [Related]
10. Induction Immunosuppressive Therapy Use in Deceased Donor Kidney Transplantation: 11-Year Experience in Veracruz, Mexico.
Martinez-Mier G; Soto-Miranda E; Avila-Pardo SF; Budar-Fernandez LF; Mateu-Rivera LJ; Mendez-Lopez MT; Trujillo-Martinez MF; Uscanga-Montesano A; Avila Y Falfan D
Transplant Proc; 2016 Mar; 48(2):600-4. PubMed ID: 27110011
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
[TBL] [Abstract][Full Text] [Related]
12. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
[TBL] [Abstract][Full Text] [Related]
14. Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients.
Klem P; Cooper JE; Weiss AS; Gralla J; Owen P; Chan L; Wiseman AC
Transplantation; 2009 Oct; 88(7):891-6. PubMed ID: 19935460
[TBL] [Abstract][Full Text] [Related]
15. Rabbit antithymocyte globulin induction therapy in adult renal transplantation.
Hardinger KL
Pharmacotherapy; 2006 Dec; 26(12):1771-83. PubMed ID: 17125438
[TBL] [Abstract][Full Text] [Related]
16. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.
Carrier M; Leblanc MH; Perrault LP; White M; Doyle D; Beaudoin D; Guertin MC
J Heart Lung Transplant; 2007 Mar; 26(3):258-63. PubMed ID: 17346628
[TBL] [Abstract][Full Text] [Related]
17. Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy.
Laftavi MR; Patel S; Soliman MR; Alnimri M; Kohli R; Said M; Pankewycz O
Transplant Proc; 2011 Mar; 43(2):466-8. PubMed ID: 21440735
[TBL] [Abstract][Full Text] [Related]
18. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
[TBL] [Abstract][Full Text] [Related]
19. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
Flaman F; Zieroth S; Rao V; Ross H; Delgado DH
J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
[TBL] [Abstract][Full Text] [Related]
20. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.
Ruggenenti P; Codreanu I; Cravedi P; Perna A; Gotti E; Remuzzi G
Clin J Am Soc Nephrol; 2006 May; 1(3):546-54. PubMed ID: 17699258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
